X-Cor Therapeutics

X-Cor Therapeutics, Inc.Founded in 2017 and headquartered in Boston, US, X-Cor Therapeutics, Inc. focuses on creating advanced medical devices that improve patient care in respiratory failure scenarios. The team includes founders Brian Chang, Jayon Wang, and Steven Keller, with Jayon Wang currently serving as CEO.X-Cor Therapeutics specializes in the development of a pioneering medical device that enables the extracorporeal removal of carbon dioxide from patients suffering from hypercarbic respiratory failure. The key product is a hybrid consumable cartridge that effectively removes CO2 using ultra-low blood flow rates of less than 300 ml/min, making it a less invasive alternative to traditional methods that require higher flow rates and specialized interventions.While specific revenue figures are not disclosed, X-Cor Therapeutics operates on a business model that likely involves direct sales to healthcare facilities and partnerships with medical institutions. The revenue structure is expected to include B2B engagements where hospitals procure the CO2 removal devices directly. The funds will support the introduction of new products designed for improved CO2 removal and the enhancement of existing technologies. The company is targeting expansion into various geographical regions to increase market presence, aiming to establish its products in healthcare systems that address respiratory illnesses effectively.

1. Seed

   Nov 12, 2020

   Amount

   $2.6M

   Investors

   Locked